NASDAQ:TMDX TransMedics Group - TMDX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $75.04 +1.75 (+2.39%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$73.30▼$76.3050-Day Range$56.19▼$82.3352-Week Range$20.36▼$83.48Volume276,187 shsAverage Volume456,991 shsMarket Capitalization$2.42 billionP/E RatioN/ADividend YieldN/APrice Target$71.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media TransMedics Group MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside4.6% Downside$71.57 Price TargetShort InterestHealthy4.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.06Based on 5 Articles This WeekInsider TradingSelling Shares$12.51 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.89) to ($0.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector637th out of 988 stocksElectromedical Equipment Industry13th out of 24 stocks 2.4 Analyst's Opinion Consensus RatingTransMedics Group has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.57, TransMedics Group has a forecasted downside of 4.6% from its current price of $75.04.Amount of Analyst CoverageTransMedics Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.66% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TransMedics Group has recently increased by 11.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMDX. Previous Next 3.4 News and Social Media Coverage News SentimentTransMedics Group has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for TransMedics Group this week, compared to 2 articles on an average week.Search Interest14 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,508,017.00 in company stock.Percentage Held by InsidersOnly 8.70% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions88.58% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TransMedics Group are expected to grow in the coming year, from ($0.89) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is -60.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is -60.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 12.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TransMedics Group (NASDAQ:TMDX) StockTransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.Read More Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address TMDX Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives $71.57 Average Price Target from AnalystsMarch 17, 2023 | finance.yahoo.comMarket Sentiment Around Loss-Making TransMedics Group, Inc. (NASDAQ:TMDX)March 21, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 11, 2023 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Sets New 12-Month High at $83.48February 24, 2023 | msn.comWhy TransMedics Stock Was a Big Star This WeekFebruary 23, 2023 | msn.comTransMedics Group Soars after Earnings and Guidance BeatFebruary 23, 2023 | finanznachrichten.deTransMedics Group, Inc.: TransMedics Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 22, 2023 | finance.yahoo.comTransMedics Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 21, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …February 21, 2023 | finance.yahoo.comTransMedics to Present at Upcoming March Investor ConferencesFebruary 17, 2023 | markets.businessinsider.comLooking for Powerful Healthcare Stocks? These 5 Made Enormous Profit in 2022February 8, 2023 | finance.yahoo.comTransMedics to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023February 2, 2023 | finance.yahoo.comTransMedics Appoints Nick Corcoran as Senior Vice President of Supply Chain and OperationsJanuary 24, 2023 | seekingalpha.comTMDX TransMedics Group, Inc.January 21, 2023 | reuters.comTMDX.OQ - | Stock Price & Latest News | ReutersJanuary 18, 2023 | nasdaq.comTransMedics Group Reaches Analyst Target PriceDecember 21, 2022 | finance.yahoo.comTransMedics to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceDecember 17, 2022 | seekingalpha.comMy Top Pick For 2023: TransMedics GroupDecember 8, 2022 | finance.yahoo.com2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023November 17, 2022 | finance.yahoo.comTransMedics (TMDX) is a Great Momentum Stock: Should You Buy?November 9, 2022 | finance.yahoo.comTransMedics Group Third Quarter 2022 Earnings: Beats ExpectationsNovember 7, 2022 | msn.comTransMedics Is Crushing It. Are Investors Overpaying?November 6, 2022 | finance.yahoo.comTransMedics Group (NASDAQ:TMDX) shareholder returns have been stellar, earning 230% in 3 yearsNovember 5, 2022 | seekingalpha.comTransMedics Group, Inc. (TMDX) Q3 2022 Earnings Call TranscriptNovember 4, 2022 | finance.yahoo.comTransMedics (TMDX) Reports Q3 Loss, Tops Revenue EstimatesNovember 4, 2022 | finance.yahoo.comTransMedics Clocks Small-Than-Expected Q3 Loss, Boosts FY22 GuidanceOctober 20, 2022 | seekingalpha.comTransMedics Remains A Buy Heading Into Q3 EarningsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address TMDX Company Calendar Last Earnings2/22/2023Today3/20/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TMDX CUSIPN/A CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees148Year FoundedN/APrice Target and Rating Average Stock Price Forecast$71.57 High Stock Price Forecast$85.00 Low Stock Price Forecast$45.00 Forecasted Upside/Downside-4.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,230,000.00 Net Margins-38.77% Pretax Margin-38.70% Return on Equity-29.82% Return on Assets-18.27% Debt Debt-to-Equity Ratio0.31 Current Ratio10.66 Quick Ratio9.79 Sales & Book Value Annual Sales$93.46 million Price / Sales25.85 Cash FlowN/A Price / Cash FlowN/A Book Value$5.87 per share Price / Book12.78Miscellaneous Outstanding Shares32,200,000Free Float29,395,000Market Cap$2.42 billion OptionableNot Optionable Beta1.47 Key ExecutivesWaleed H. HassaneinPresident, Chief Executive Officer & DirectorJohn F. CareyVice President-OperationsStephen GordonChief Financial Officer, Secretary & TreasurerMark AndersonSenior Director-Technology DevelopmentJohn SullivanVice President-Quality & EngineeringKey CompetitorsIntegerNYSE:ITGRInModeNASDAQ:INMDLivaNovaNASDAQ:LIVNCONMEDNYSE:CNMDOutset MedicalNASDAQ:OMView All CompetitorsInsiders & InstitutionsWaleed H HassaneinSold 7,500 sharesTotal: $605,400.00 ($80.72/share)Stephen GordonSold 5,000 sharesTotal: $397,550.00 ($79.51/share)Edward M BasileSold 3,500 sharesTotal: $280,350.00 ($80.10/share)Voya Investment Management LLCBought 19,148 shares on 2/28/2023Ownership: 0.096%Tamer I KhayalSold 10,000 sharesTotal: $801,500.00 ($80.15/share)View All Insider TransactionsView All Institutional Transactions TMDX Stock - Frequently Asked Questions Should I buy or sell TransMedics Group stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TMDX shares. View TMDX analyst ratings or view top-rated stocks. What is TransMedics Group's stock price forecast for 2023? 7 brokers have issued 1 year target prices for TransMedics Group's stock. Their TMDX share price forecasts range from $45.00 to $85.00. On average, they anticipate the company's share price to reach $71.57 in the next year. This suggests that the stock has a possible downside of 4.6%. View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts. How have TMDX shares performed in 2023? TransMedics Group's stock was trading at $61.72 on January 1st, 2023. Since then, TMDX shares have increased by 21.6% and is now trading at $75.04. View the best growth stocks for 2023 here. When is TransMedics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our TMDX earnings forecast. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings data on Wednesday, February, 22nd. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07. The firm earned $31.38 million during the quarter, compared to analyst estimates of $23.60 million. TransMedics Group had a negative net margin of 38.77% and a negative trailing twelve-month return on equity of 29.82%. The firm's quarterly revenue was up 224.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.46) EPS. What ETFs hold TransMedics Group's stock? ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), Alger 35 ETF (ATFV), Changebridge Capital Long/Short Equity ETF (CBLS), Changebridge Capital Sustainable Equity ETF (CBSE), SPDR S&P Health Care Equipment ETF (XHE), Invesco DWA SmallCap Momentum ETF (DWAS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Principal Healthcare Innovators ETF (BTEC). What guidance has TransMedics Group issued on next quarter's earnings? TransMedics Group issued an update on its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$145.00 million, compared to the consensus revenue estimate of $134.71 million. What is Waleed Hassanein's approval rating as TransMedics Group's CEO? 17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS). When did TransMedics Group IPO? (TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. What is TransMedics Group's stock symbol? TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX." Who are TransMedics Group's major shareholders? TransMedics Group's stock is owned by many different retail and institutional investors. Top institutional investors include Macquarie Group Ltd. (6.10%), Sandhill Capital Partners LLC (3.77%), Lord Abbett & CO. LLC (3.72%), Driehaus Capital Management LLC (3.45%), Credit Suisse AG (3.25%) and Summit Partners Public Asset Management LLC (3.00%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TransMedics Group's stock price today? One share of TMDX stock can currently be purchased for approximately $75.04. How much money does TransMedics Group make? TransMedics Group (NASDAQ:TMDX) has a market capitalization of $2.42 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. How many employees does TransMedics Group have? The company employs 148 workers across the globe. How can I contact TransMedics Group? TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com. This page (NASDAQ:TMDX) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.